WANBURY LIMITED Share Price

WANBURY LIMITED Share Price

NSE: WANBURY
|
Pharmaceuticals
|
S Cap
₹ 0.00
+0.00 (0.00%)
1D
--
--
--
1D LOW
1D HIGH

WANBURY LIMITED Returns Calculator

Circuit
L
H
--
--
52-week
L
H
--
--

About WANBURY LIMITED

WANBURY LIMITED Share Price
ISIN
INE107F01022
Sector Market Cap
₹ 878.89 Cr

Wanbury Limited is an India-based pharmaceutical company with a presence in the active pharmaceutical ingredients (APIs) global market and domestic branded formulations. The Company is engaged in the business of pharmaceutical and related activities, including research. Its API products include Metformin, Metformin Dc, Tramadol, Sertraline, Diphenhydramine HCL, Diphenhydramine Citrate, Mefenamic Acid, Paroxetine Hemihydrate, Promethazine, Glucosamine, Clopidogrel, Levetiracetam and Carvedilol Phosphate Monohydrate. In formulations, the Company has a presence across various therapeutic categories, such as cough and cold solutions, gynecology, orthopedics, nutraceuticals, gastrointestinal, anti-inflammatory and analgesics. The Company is also focused on the development of products like ketamine, rivaroxaban, montelukast, sitagliptin and a few others to reduce dependency on metformin and sertraline. The Company has facilities in Tanuku, Andra Pradesh, and Patalganga, Maharashtra.

WANBURY LIMITED Financial Highlights

  • Revenue: WANBURY LIMITED reported revenue of ₹603.00 crore in FY25 vs ₹578.64 crore in FY24. It showed an increase of 4.21% on a yearly basis.
  • Operating Profit: WANBURY LIMITED reported an operating profit of ₹29.55 crore in FY25 vs ₹56.34 crore in FY24. It showed a decrease of 47.55% on a year-on-year basis.
  • Net Profit: WANBURY LIMITED reported a net profit of ₹30.53 crore in FY25 vs ₹55.96 crore in FY24. It showed a decrease of 45.44% on a yearly basis.

WANBURY LIMITED Quarterly Result Highlights

  • WANBURY LIMITED reported revenue of ₹163.53 crore in Jun 2025, compared with ₹173.84 crore in Mar 2025, representing a decrease of 5.93% on a quarter-on-quarter (QoQ) basis.
  • WANBURY LIMITED reported an operating profit of ₹13.61 crore in Jun 2025, compared with ₹19.05 crore in Mar 2025, representing a decrease of 28.56% on a quarter-on-quarter (QoQ) basis.
  • WANBURY LIMITED reported a profit of ₹13.49 crore in Jun 2025, compared with ₹20.26 crore in Mar 2025, reflecting a decrease of 33.42% on a QoQ basis.
  • The earnings per share (EPS) of WANBURY LIMITED stood at ₹9.32 during Jun 2025.
Know more
Promoters
43.02%
FII
0.89%
Other DII
0.06%
Retail and other
56.03%
Mutual funds
0.00%
Foreign institutions - FII
FII shareholding by period
Sep 20250.82%
Dec 20250.72%
Mar 20260.59%
Jun 20260.89%
Mkt Cap Cr
878.89
P/E
21.41
P/B
11.88
ROE
51.51%
D/E
1.55
ROCE
27.98%
Div. Yield
0.00%
EPS(TTM)
20.42
Turnover
1.26
EV/EBITDA
11.38
Net Margin
0.00%
Op. Margin
0.00%
ROA
10.39%
Quick Ratio
0.00
Curr. Ratio
1.89
Based on fundamentals, this stock's
Step 1 of 5
Performance
Very Poor
Wanbury has not beaten FD return of 7%
Step 1 of 5
Valuation
Overvalued
Wanbury appears overvalued compared to its peers
Step 2 of 5
Earnings
Poor
Wanbury earnings have been degrowing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Sun Pharmaceutical Industries4,64,271.0038.325.5613.74%0.6117.33%93.240.83%0.4810.90
Divis Laboratories2,26,843.0077.5513.5315.32%0.0019.56%629.490.35%0.5598.19
Torrent Pharmaceuticals1,86,000.0086.2722.1225.49%1.6913.85%222.760.69%0.4958.70
Zydus Lifesciences1,20,099.0026.154.4318.59%0.3117.35%237.300.08%0.3335.38
Cipla1,18,027.0035.183.4311.27%0.0014.95%423.360.89%0.4543.52
Lupin1,03,549.0018.624.6123.76%0.0424.88%659.050.79%0.57129.18
Mankind Pharma1,00,137.0048.436.1411.74%0.3413.13%397.020.04%0.4449.37
Dr. Reddy's Laboratories1,00,073.0031.442.6311.07%0.1812.54%377.960.67%0.4138.68
Laurus Labs99,474.2091.2318.7716.77%0.4016.14%97.200.11%0.6713.72
Aurobindo Pharma96,700.6026.062.559.25%0.1911.76%391.140.24%0.3841.58

WANBURY LIMITED Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Revenue₹599.51₹575.65₹499.65₹511.19
Other Income₹3.49₹2.99₹0.91₹1.51
Total Revenue₹603.01₹578.64₹500.56₹512.69
Total Expenses₹573.46₹547.86₹510.25₹507.93
Profit Before Tax₹29.55₹56.34-₹10.29₹81.13
Tax-₹0.98₹0.38₹0.11-₹0.35
Profit After Tax₹30.53₹55.96-₹10.40₹81.47
EPS - Basic₹9.32₹17.10-₹3.18₹25.29
EPS - Diluted₹8.98₹16.89-₹3.18₹25.21

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Profit before tax₹29.55₹56.34-₹10.29₹81.13
Income before WC changes₹77.53₹72.39₹26.72₹37.45
Change in Assets-₹30.39-₹36.09₹27.33-₹60.30
Change in Liabilities-₹20.66-₹32.14-₹34.08₹63.54
Change in WC-₹51.06-₹68.23-₹6.75₹3.24
Cash flow from Operations₹26.10₹3.98₹19.80₹40.52
Cash flow from Investing-₹51.17-₹16.63-₹8.84₹0.59
Cash flow from Financing₹25.73₹14.55-₹31.99-₹28.58
Total Cash Flow₹0.66₹1.91-₹21.03₹12.52
Cash (Start of the year)₹3.40₹1.49₹22.53₹10.00
Cash (End of the year)₹4.06₹3.40₹1.49₹22.53

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Non-Current Assets₹220.47₹184.21₹181.71₹181.31
Current Assets₹193.44₹159.29₹121.81₹171.24
Total Assets₹413.92₹343.49₹303.52₹352.55
Current Liabilities₹174.61₹214.11₹320.03₹359.77
Net Current Asset₹18.83-₹54.82-₹198.22-₹188.53
Non-Current Liabilities₹180.03₹101.45₹16.31₹16.20
Equity Capital₹59.27₹27.94-₹32.82-₹23.42
Total Equity & Liabilities₹413.92₹343.49₹303.52₹352.55

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Revenue₹599.51₹577.74₹499.65₹511.19
Other Income₹3.49₹0.90₹0.91₹1.51
Total Revenue₹603.01₹578.64₹500.56₹512.69
Total Expenses₹573.46₹547.86₹510.25₹507.93
Profit Before Tax₹29.55₹30.78-₹10.29₹81.13
Tax-₹0.98₹0.38₹0.11-₹0.35
Profit After Tax₹30.53₹30.40-₹10.40₹81.47
EPS - Basic₹9.32₹9.29-₹3.18₹25.29
EPS - Diluted₹8.98₹9.18-₹3.18₹25.21

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Profit before tax₹29.55₹30.78-₹10.29₹81.13
Income before WC changes₹77.53₹72.39₹26.72₹37.45
Change in Assets-₹30.39-₹38.45₹27.36-₹60.31
Change in Liabilities-₹20.66-₹29.06-₹34.11₹63.55
Change in WC-₹51.06-₹67.51-₹6.75₹3.24
Cash flow from Operations₹26.10₹4.70₹19.80₹40.52
Cash flow from Investing-₹51.17-₹16.63-₹8.84₹0.59
Cash flow from Financing₹25.73₹13.87-₹31.99-₹28.58
Total Cash Flow₹0.66₹1.94-₹21.03₹12.53
Cash (Start of the year)₹3.40₹1.46₹22.49₹9.96
Cash (End of the year)₹4.06₹3.40₹1.46₹22.49

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Non-Current Assets₹220.47₹184.51₹181.71₹181.31
Current Assets₹193.44₹158.61₹120.19₹169.69
Total Assets₹413.92₹343.12₹301.90₹351.00
Current Liabilities₹174.61₹210.70₹292.84₹332.62
Net Current Asset₹18.83-₹52.09-₹172.66-₹162.93
Non-Current Liabilities₹180.03₹104.48₹16.31₹16.20
Equity Capital₹59.27₹27.94-₹7.26₹2.19
Total Equity & Liabilities₹413.92₹343.12₹301.90₹351.00
* All values are in INR Crore
Qty
Bid
Ask
Qty
Bid Total: 0
Ask Total: 0
Buy orders: 0%
Sell orders: 0%
Bearish
2
Neutral
4
Bullish
2
Neutral
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
33.33
Neutral
ATR (14)
20.34
Neutral
STOCH(9,6)
29.74
Neutral
STOCH RSI (14)
19.76
Bullish
ADX(9)
37.53
Bearish
UO(9)
43.89
Neutral
ROC(12)
-19.64
Bearish
WillR(14)
-81.33
Bullish
Period
Simple value
Exponential vaue
5D
258.48
261.7
10D
272.75
272.63
20D
301.03
285.19
50D
287.33
286.31
100D
271.19
275.98
Volume trend — traded volume by day
13 Aug5L
12 Aug25L
11 Aug13L
10 Aug5L
7 Aug5L
Average11L
Compare against other stocks
WANBURY LIMITED Share Price
WANBURY LIMITED
Pharmaceuticals
Add Stock
Add Another

WANBURY LIMITED Share Price FAQs